Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Sunday 1 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

R&D

Cargo vessels in Straight of Hormuz

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

Oncology

Hengrui exhibition booth at ESMO 2026

Sponsored

Global oncology innovation from Hengrui Pharma

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Patients

HCP talks to patient in clinical trial

Why “rare disease” is a regulatory label, not a patient real...

Regulators define a rare disease by how many people have it, and the answer depends on who is counting.

Digital

Agentic AI concept

Sponsored

4 Questions pharma leaders can’t skip before letting AI act

Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.

Digital

pharmaphorum podcast Episode 284, Mati Gill, AION Labs

AI, start-ups, and the future of human health: AION Labs’ Ma...

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Articles

A beginner’s guide to digital pharma: part 9 – mobile apps!

A beginner’s guide to digital pharma: part 9 – mobile apps!

We’re on the move in the latest part of our beginner’s guide to digital pharma. Welcome to the world of mobile apps, which might just change the face of healthcare forever. When I got up this morning I found myself feeling a bit groggy, so decided to check my sleep cycle app on my iPhone to see when I slept most during the night…

Articles

A beginner’s guide to digital pharma: part 11 – SEO

A beginner’s guide to digital pharma: part 11 – SEO

Did you find this article through Google? If so, then SEO played a part and in our latest piece on all things digital we explain how to make your brand visible to the search engines. There is so much to say about the “art” of search engine optimisation, or SEO as it’s commonly called, that it’s hard to know where to begin…

Articles

A beginner’s guide to digital pharma: part 12 – email marketing

A beginner’s guide to digital pharma: part 12 – email market...

Ever gone to a website via a marketing email that caught your attention? This week we explore email marketing and find it’s not all spam if done the right way! Well, we said we’d cover email and mobile marketing this week, but then we decided these areas were so important that we decided to cover them one at a time…

Load more results

Sales & Marketing

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

The dangers of social media for pharma

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Digital

Agentic AI concept

Sponsored

4 Questions pharma leaders can’t skip before letting AI act

Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.

Digital

pharmaphorum podcast Episode 284, Mati Gill, AION Labs

AI, start-ups, and the future of human health: AION Labs’ Ma...

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Roche offers $15bn for strategic-level deal with Hansoh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Clinical trial setup times fall sharply in UK

Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Hengrui exhibition booth at ESMO 2026

Sponsored

Global oncology innovation from Hengrui Pharma

Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.

Oncology

AI targeting cancer cell graphic

How AI is advancing patient subgroup identification in oncol...

With the advent of AI, it’s now possible to enrich clinical trials for patient subgroups more precisely than ever before.

Oncology

San Diego, CA skyline

Personal reflections on World ADC, San Diego

At World ADC this month, the latest advances in ADC discovery and development were presented, debated, and reflected upon.

Patients

Patients

HCP talks to patient in clinical trial

Why “rare disease” is a regulatory label, not a patient real...

Regulators define a rare disease by how many people have it, and the answer depends on who is counting.

Patients

pharmaphorum podcast Episode 281 - Cecilia Caetano, Bayer

Sponsored

Menopause is an urgent global health issue: Bayer’s Cecilia ...

Patients

female HCP confers with female patient

From bedside to breakthroughs: Reimagining the human experie...

Patients should be involved in the programme design process from the beginning, as co-creators with full influence over the outcome.

R&D

R&D

Cargo vessels in Straight of Hormuz

Navigating geopolitical risks: Practical and legal mitigatio...

Geopolitical risk is now front of mind for many pharmaceutical leaders.

R&D

Auto vacuum sealed vaccines in manufacturing plant

Reliability in life sciences logistics: What good looks like

What constitutes a reliable supply chain is changing rapidly.

R&D

Heart on ECG digital graphic

Cardiovascular disease today: NMR-based lipoprotein profilin...

pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.

Editor's Picks

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Roche offers $15bn for strategic-level deal with Hansoh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Clinical trial setup times fall sharply in UK

Despite US policy changes, drug prices stay stubbornly high

News

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company